14.38
price down icon3.75%   -0.56
after-market After Hours: 14.39 0.010 +0.07%
loading
Arcturus Therapeutics Holdings Inc stock is traded at $14.38, with a volume of 337.80K. It is down -3.75% in the last 24 hours and up +7.88% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$14.94
Open:
$14.93
24h Volume:
337.80K
Relative Volume:
0.77
Market Cap:
$389.99M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-12.40
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
+4.28%
1M Performance:
+7.88%
6M Performance:
-12.16%
1Y Performance:
-40.26%
1-Day Range:
Value
$14.24
$15.18
1-Week Range:
Value
$13.83
$15.83
52-Week Range:
Value
$8.04
$25.88

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
Name
Arcturus Therapeutics Holdings Inc
Name
Phone
(858) 900-2660
Name
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
176
Name
Twitter
@ArcturusRx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ARCT's Discussions on Twitter

Compare ARCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARCT
Arcturus Therapeutics Holdings Inc
14.38 405.18M 157.75M -29.73M -21.00M -1.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-28-25 Initiated Scotiabank Sector Outperform
Jan-28-25 Initiated BTIG Research Buy
Aug-12-24 Initiated Leerink Partners Outperform
Dec-13-23 Initiated Canaccord Genuity Buy
Jul-24-23 Initiated William Blair Outperform
May-11-23 Upgrade H.C. Wainwright Neutral → Buy
Nov-14-22 Resumed Wells Fargo Overweight
Nov-10-22 Downgrade Robert W. Baird Neutral → Underperform
Nov-03-22 Upgrade Citigroup Neutral → Buy
Nov-02-22 Upgrade Barclays Underweight → Equal Weight
Aug-10-22 Downgrade Raymond James Mkt Perform → Underperform
Jul-19-22 Resumed Cantor Fitzgerald Overweight
May-11-22 Upgrade Robert W. Baird Underperform → Neutral
Apr-21-22 Downgrade Citigroup Buy → Neutral
Jan-31-22 Upgrade Raymond James Underperform → Mkt Perform
Aug-12-21 Downgrade Raymond James Mkt Perform → Underperform
Aug-11-21 Downgrade Goldman Neutral → Sell
Aug-10-21 Downgrade Robert W. Baird Neutral → Underperform
Jul-02-21 Initiated Cantor Fitzgerald Overweight
Jun-25-21 Resumed Goldman Neutral
Jun-21-21 Downgrade Barclays Equal Weight → Underweight
Jun-04-21 Resumed Robert W. Baird Neutral
Feb-17-21 Downgrade B. Riley Securities Neutral → Sell
Jan-19-21 Downgrade B. Riley Securities Buy → Neutral
Jan-15-21 Downgrade B. Riley Securities Buy → Neutral
Jan-07-21 Initiated Wells Fargo Overweight
Dec-29-20 Downgrade Barclays Overweight → Equal Weight
Dec-29-20 Downgrade H.C. Wainwright Buy → Neutral
Dec-29-20 Downgrade Raymond James Outperform → Mkt Perform
Dec-29-20 Downgrade Robert W. Baird Outperform → Neutral
Dec-23-20 Downgrade ROTH Capital Buy → Sell
Dec-08-20 Reiterated B. Riley Securities Buy
Dec-07-20 Reiterated B. Riley Securities Buy
Oct-26-20 Initiated Barclays Overweight
Oct-06-20 Initiated Citigroup Buy
Aug-26-20 Initiated Piper Sandler Overweight
Jul-30-20 Resumed ROTH Capital Buy
Jul-16-20 Initiated Raymond James Outperform
Jul-13-20 Initiated B. Riley FBR Buy
Jun-09-20 Downgrade WBB Securities Buy → Hold
Feb-11-20 Initiated Robert W. Baird Outperform
Feb-07-20 Initiated Guggenheim Buy
Feb-06-20 Initiated Guggenheim Buy
Apr-05-19 Initiated H.C. Wainwright Buy
Sep-20-18 Upgrade WBB Securities Buy → Strong Buy
Jan-22-18 Initiated Chardan Capital Markets Buy
View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

pulisher
04:00 AM

New York State Common Retirement Fund Sells 1,100 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

04:00 AM
pulisher
12:03 PM

What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Unlock powerful trading strategies for gains - jammulinksnews.com

12:03 PM
pulisher
Jul 27, 2025

Does Arcturus Therapeutics Holdings Inc. stock perform well during market downturnsBuild wealth faster with disciplined trading - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Arcturus Therapeutics Holdings Inc. stock price move sharplyBuild wealth steadily with proven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Arcturus Therapeutics Holdings Inc. Stock Support and Resistance Levels You Should KnowFree Stock Market Swing Trading Strategies - Metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsInvest smarter with daily market updates - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversBuild your wealth with consistent stock growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityMomentum Swing Watchlist - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Is Arcturus Therapeutics Holdings Inc. Stock Overbought or Oversold RSI Indicator AnalysisMinimized Risk Maximum Return - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Arcturus Therapeutics Holdings Inc. stockInvest confidently with data-driven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is Arcturus Therapeutics Holdings Inc. a good long term investmentFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Does Arcturus Therapeutics Holdings Inc. stock pay reliable dividendsOutstanding capital returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Arcturus Therapeutics Holdings Inc. stockExceptional trading performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Arcturus Therapeutics Holdings Inc. stock priceConsistent high-yield stocks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Arcturus Therapeutics Holdings Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Arcturus Therapeutics to Attend Upcoming Investor ConferencesJuly 23, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 19, 2025

What drives PLUR stock priceRobust investment performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Best Stocks for Aggressive Growth Pro Stock Market SignalsFree Consultation - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

What drives KSPI stock priceFree Stock Market Forecast Reports - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $54.00 Consensus PT from Analysts - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser

Jul 15, 2025

Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):